1450621-83-6

Basic information

• Product Name: 2-(6-((2S)-4-benzyl-2-(1-propyn-1-yl)-1-piperazinyl)-5-chloro-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol
• Synonyms: 2-(6-((2S)-4-benzyl-2-(1-propyn-1-yl)-1-piperazinyl)-5-chloro-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol
• CAS NO: 1450621-83-6
• Molecular Weight: 491.864
• Mol File: 1450621-83-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(6-((2S)-4-benzyl-2-(1-propyn-1-yl)-1-piperazinyl)-5-chloro-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-((2S)-4-benzyl-2-(1-propyn-1-yl)-1-piperazinyl)-5-chloro-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol(1450621-83-6)
• EPA Substance Registry System: 2-(6-((2S)-4-benzyl-2-(1-propyn-1-yl)-1-piperazinyl)-5-chloro-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol(1450621-83-6)

Safety Data

• Hazardous Substances Data: 1450621-83-6(Hazardous Substances Data)

Upstream product

• 41667-95-2 5,6-dichloronicotinic acid 
• 54127-29-6 5,6-dichloronicotinoyl chloride 
• 1450620-25-3 (3S)-1-benzyl-3-(1-propyn-1-yl)piperazine 
• 1450620-28-6 2-(5,6-dichloro-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1450621-79-0 (3S)-1-benzyl-3-(2-propyn-1-yl)-piperazine 
• 1450621-78-9 (3S)-1-benzyl-3-(2-propyn-1-yl)-2,5-piperazinedione 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 1450621-77-8 ethyl 2-[benzyl-[(2S)-2-(tert-butoxycarbonylamino)pent-4-ynoyl]amino]acetate 

Relevant articles and documents

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket

Structure-activity relationship investigations conducted at the 5-position of the N-pyridine ring of a series of N-arylsulfonyl-N′-2-pyridinyl- piperazines led to the identification of a novel bis-pyridinyl piperazine sulfonamide (51) that was a potent disruptor of the glucokinase-glucokinase regulatory protein (GK-GKRP) interaction. Analysis of the X-ray cocrystal of compound 51 bound to hGKRP revealed that the 3-pyridine ring moiety occupied a previously unexplored binding pocket within the protein. Key features of this new binding mode included forming favorable contacts with the top face of the Ala27-Val28-Pro29 ("shelf region") as well as an edge-to-face interaction with the Tyr24 side chain. Compound 51 was potent in both biochemical and cellular assays (IC50 = 0.005 μM and EC 50 = 0.205 μM, respectively) and exhibited acceptable pharmacokinetic properties for in vivo evaluation. When administered to db/db mice (100 mg/kg, po), compound 51 demonstrated a robust pharmacodynamic effect and significantly reduced blood glucose levels up to 6 h postdose.